Comparison

ABBOTT LABORATORIES (ABT) vs STRYKER CORP (SYK)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ABT

ABBOTT LABORATORIES

Medical Devices

Revenue, FY25: $44.33B
Net income: $6.52B
Operating cash flow: $9.57B
Free cash flow: $7.4B
Net margin: 14.72%
Operating margin: 18.17%
Gross margin: 56.42%

SYK

STRYKER CORP

Medical Devices

Revenue, FY25: $25.12B
Net income: $3.25B
Operating cash flow: $5.04B
Free cash flow: $4.28B
Net margin: 12.92%
Operating margin: 19.47%
Gross margin: 63.96%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ABT	SYK
Revenue growth, latest filed year	+5.67%	+11.16%
Piotroski F-score	6 of 9	4 of 9
P/E against its own history	15.41% below	34.28% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ABT

Currency moves
Cybersecurity
Product recalls
FDA approval
Litigation
Supply chain

And 15 more.

SYK

Pandemic
Currency moves
Litigation
Product recalls
Tax
Reimbursement

And 21 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.10% · 0.09%

Updated Aug 20, 2026 · the newer of the two companies' filings